Lyell Q4/FY25 net loss $274.4M; Phase 3 PiNACLE-H2H begins; cash $247.2M

Lyell Immunopharma, Inc.

FY25 net loss $274.4M vs $343.0M in FY24; Q4 net loss $140.7M (incl. $66.3M IPR&D for LYL273).
Ronde-cel Phase 3 PiNACLE-H2H (2L LBCL) started dosing; Phase 1/2 PiNACLE 3L+ data shown at ASH 2025.
LYL273 (GCC-targeted CAR-T) Phase 1 dosed 7 more mCRC patients; no DLT; dose escalated to Level 3.
Smital Shah appointed CFO and Business Officer in March 2026; $50M equity tranche closed on milestone.
Cash $247.2M at year-end 2025 (excl. $50M tranche); runway into Q2 2027.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.